New tirapazamine derivatives protect cardiomyocytes from doxorubicin toxicity
Agnieszka Korga-Plewko(Medical University of Lublin), Jarosław Dudka(Medical University of Lublin), Elżbieta Szacoń(Medical University of Lublin), Magdalena Iwan(Medical University of Lublin), Dariusz Matosiuk(Medical University of Lublin), Marta Ostrowska-Leśko(Medical University of Lublin), Marzena Rządkowska(Medical University of Lublin), Marcin Sysa(Medical University of Lublin), Ewelina Humeniuk(Medical University of Lublin)
Cited by 3
Related Papers
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics
|Neuropharmacology|2019|81
Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells
|BMC Pharmacology and Toxicology|2019|61
Inhibition of glycolysis disrupts cellular antioxidant defense and sensitizes HepG2 cells to doxorubicin treatment
|FEBS Open Bio|2019|50
The effect of a number of H9C2 rat cardiomyocytes passage on repeatability of cytotoxicity study results
|Cytotechnology|2016|48
The Role of Molecular and Inflammatory Indicators in the Assessment of Cognitive Dysfunction in a Mouse Model of Diabetes
|International Journal of Molecular Sciences|2021|43